Pulmonx (NASDAQ:LUNG) shares fell 10.1% to $2.05 in premarket trading, with no specific company announcement identified in the source material as a catalyst for the move.
The decline follows a period in which Pulmonx shares had risen from their 52-week low of $1.13. The company’s next earnings release is currently estimated for November 10, 2026.
Pulmonx Reports Recent Employee Equity Grants
On September 1, Pulmonx disclosed inducement equity grants covering a total of 52,300 restricted stock units awarded to four newly hired employees.
The grants represented the company’s most recent corporate disclosure cited in the source material.
Pulmonx’s previous quarterly results, released in late July, showed worldwide revenue declining 5% year over year during the second quarter of 2026.
According to the source material, analysts characterised management’s commentary accompanying those results as cautious.
Broader Market Trades Slightly Lower
The Nasdaq Composite was modestly lower during the period, providing a weaker broader market backdrop for Pulmonx shares.
The source material also noted that recent disclosed insider activity had included sales and no recorded insider purchases.
In the absence of a specific new corporate announcement, the precise reason for Pulmonx’s 10.1% premarket decline could not be determined from the information provided.
Pulmonx stock price
